beta

You're viewing our new website - find out more

Publication - Consultation Paper

Clinical Trial Access quality performance indicator: consultation

Published: 3 Jul 2017
Part of:
Health and social care
ISBN:
9781788510912

Consultation on the effectiveness of the Clinical Trial Access quality performance indicator (QPI) as part of the National Cancer QPIs.

20 page PDF

492.4kB

20 page PDF

492.4kB

Contents
Clinical Trial Access quality performance indicator: consultation
7. Methodology

20 page PDF

492.4kB

7. Methodology

The clinical trials QPI will be measured utilising SCRN data and ISD incidence data, as is the methodology currently utilised by the Chief Scientist Office ( CSO) and NCRI. The principal benefit of this approach is that this data is already collected utilising a robust mechanism. At present a 'clinical trial' data item is contained within all tumour specific datasets, however in order to avoid any duplication of effort, and focus resources appropriately, SCRN data is the preferred option.

Utilising SCRN data allows for comparison with CSO published data and ensures capture of all clinical trials activity, not solely first line treatment trials, as contained in the clinical audit data. Given that a significant proportion of clinical trials are for relapsed disease this is felt to be particularly important in driving quality improvement. This methodology utilises incidence as a proxy for all patients with cancer. This may slightly over, or underestimate, performance levels, however this is an established approach currently utilised by NHSScotland.


Contact

Email: Chris Booth, chris.booth@gov.scot

Phone: 0300 244 4000 – Central Enquiry Unit

The Scottish Government
St Andrew's House
Regent Road
Edinburgh
EH1 3DG